Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT00557635
Other study ID # CHU-0026
Secondary ID
Status Suspended
Phase Phase 2
First received November 12, 2007
Last updated September 22, 2009
Start date January 2008
Est. completion date December 2011

Study information

Verified date September 2009
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

Sometime osseous reconstruction needs allogeneic bone, in this study we use Ostéopure™ from Ostéobanque d'Auvergne, which is a osseous matrix. However Ostéopure™ integration lasts a long time. To optimize this integration we purpose to associate mesenchymal progenitors cells from autologous bone marrow.


Description:

All patients will be treated for tibia or femur pseudo-arthrosis. At the beginning of chirurgical intervention, autologous bone marrow will be sampling and will be concentrated during this one.

Meanwhile osseous matrix (Ostéopure™ ) will be incubated in autologous blood serum and finally implanted in the fracture site. And after (at the end of chirurgical intervention), concentrate autologous bone marrow will be injected in the same place.


Recruitment information / eligibility

Status Suspended
Enrollment 50
Est. completion date December 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- tibia or femur pseudo-arthrosis,

- patient who needs bone graft

Exclusion Criteria:

- - contra indications for chirurgical intervention or bone graft

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Chirurgical procedure
Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate osseous setting at 3-months follow-up and compare our results with past studies at 3-months follow-up Yes
Secondary Feasibility and tolerance of this therapeutic strategy at 3-months follow-up Yes